A-674563

Catalog No. A11034

A-674563是一种B/Akt抑制剂,IC50为14 nM,并且还显示出对PKA和CDK2的抑制活性,IC50分别为16和46 nM。
  • Kobayashi T, .et al. A-674563 increases chondrocyte marker expression in cultured chondrocytes by inhibiting Sox9 degradation, Biochem Biophys Res Commun, 2018, Jan 1;495(1):1468-1475 PMID: 29196261
  • Lin Xu, .et al. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells, Biochem Biophys Res Commun, 2016, Apr 15;472(4):662-8 PMID: 26920060
  • Zou Y, .et al. Pre-clinical assessment of A-674563 as an anti-melanoma agent, Biochem Biophys Res Commun, 2016, Aug 12;477(1):1-8 PMID: 26970307
Catalog Num A11034
M. Wt 358.4
Formula C22H22N4O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 552325-73-2
Synonyms A674563
SMILES CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OC[C@H](CC4=CC=CC=C4)N
A-674563是一种B/Akt抑制剂,IC50为14 nM,并且还显示出对PKA和CDK2的抑制活性,IC50分别为16和46 nM。
Targets
Target Value
Akt1ki: 11nM
PKAki: 16nM
CDK2ki: 46nM
GSK-3βki: 110nM
ERK2ki: 260nM
PKCδki: 360nM
RSK2ki: 580nM
MAPK-AP2ki: 1.1μM
PKCγki: 1.2μM
FLT1ki: >2.2μM
Chk1ki: 2.6μM
KDRki: >3.7μM
CK2ki: 5.4μM
c-Kitki: >5.8μM
Srcki: 13μM
PDK-1ki: >20μM
In vitro (25°C) DMSO 71 mg/mL (198.08 mM)
Water 71 mg/mL (198.08 mM)
Ethanol 18 mg/mL (50.21 mM)
In vivo Saline 28 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 27.9 mL 139.51 mL 279.02 mL
0.5 mM 5.58 mL 27.9 mL 55.8 mL
1 mM 2.79 mL 13.95 mL 27.9 mL
5 mM 0.56 mL 2.79 mL 5.58 mL

*The above data is based on the productmolecular weight 358.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.